Impact of markedly elevated serum lipoprotein(a) levels (≥100 mg/dL) on the risk of coronary heart disease

Okubo, Minoru; Amemiya-Kudo, Michiyo; Hiraga, Takaki; Oka, Junko; Shimada, Masako; Igarashi, Tomio

doi:10.1016/j.metabol.2007.04.015

Cited by 16 publications

(10 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…About half of the patients, that is, 173 of the 352 patients, were receiving medications for diabetes (insulin in 46 and oral hypoglycemic agents in 127); and 62 patients (17.6%) were receiving lipid-lowering agents. Patients with end-stage renal disease and nephrotic syndrome, both of which have been reported to be associated with significant increase of the serum Lp(a) levels and increased risk of CHD [5,15], were not included.…”

Section: Study Subjectsmentioning

confidence: 99%

“…Previously, we reported a positive association between high serum Lp(a) concentrations and the risk of cardiovascular events in diabetic patients, based on the results of a prospective study [12]. Very recently, we demonstrated that markedly elevated serum Lp(a) concentrations (≥100 mg/dL) are associated with a 5-fold or greater increase in the CHD risk in patients with type 2 diabetes mellitus, as well as in patients with familial and nonfamilial hypercholesterolemia [15]. The aim of the present study was to demonstrate the impact of elevated serum Lp(a) concentrations on the risk of CHD in patients with type 2 diabetes mellitus.…”

Section: Introductionmentioning

confidence: 96%

See 1 more Smart Citation

Impact of elevated serum lipoprotein (a) concentrations on the risk of coronary heart disease in patients with type 2 diabetes mellitus

Okubo¹,

Amemiya-Kudo²,

Ebara³

et al. 2008

Metabolism

Self Cite

View full text Add to dashboard Cite

Section: Study Subjectsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 96%

Impact of elevated serum lipoprotein (a) concentrations on the risk of coronary heart disease in patients with type 2 diabetes mellitus

Okubo¹,

Amemiya-Kudo²,

Ebara³

et al. 2008

Metabolism

Self Cite

View full text Add to dashboard Cite

“…Lp(a) is an LDL-like particle which has been linked to a glycoprotein which has been named as apolipoprotein(a). There is substantial evidence to suggest that elevated serum Lp(a) levels contribute significantly to the development of CHD [1][2][3][4][5].…”

Section: Introductionmentioning

confidence: 99%

Relationship between Lipoprotein(a) and Thyroid Hormones in Hypothyroid Patients

Kaliaperumal

William

Selvam

et al. 2014

JCDR

View full text Add to dashboard Cite

Background and Objective: Changes in plasma lipid con cen trations are well known metabolic consequences of thyroid dysfunction. The alterations are most prominent in hypothyroidism which is typically associated with pronounced hypercholesterolaemia and frequently with moderate hyper triglyceridaemia. In cases of hypothyroidism, how the serum Lp(a) levels are influenced by thyroid hormone remains unknown and contradictory results on the effect of thyroid hormone on serum Lp(a) levels have been reported. There is substantial evidence to suggest that elevated serum Lp(a) levels contribute significantly to the development of CHD. The present study was designed to determine the lipoprotein(a) [Lp(a)], lipid profile and thyroid hormone levels in newly diagnosed hypothyroid patients and to find any correlation that existed between Lp(a) and other parameters.

show abstract

“…It is mainly determined genetically, depending on apoprotein (a) genotype [9,10]. The direct association between serum Lp(a) levels and the risk of cardiovascular disorders is well established [11,12]. Elevated levels of serum Lp(a) is also associated with an increased risk of coronary heart disease in patients with diabetes [13,14].…”

Section: Introductionmentioning

confidence: 99%

Serum Lipoprotein(a) Levels are Greater in Female than Male Patients with Type‐2 Diabetes

Nakhjavani¹,

Morteza²,

Esteghamati³

et al. 2010

Lipids

View full text Add to dashboard Cite

Women with diabetes are faced with a higher risk of dyslipidemia and cardiovascular disorders than men with diabetes. We aimed to study the role of gender and menopausal status in serum Lp(a) levels in patients with type 2 diabetes. We quantified serum Lp(a) levels in a group of 477 patients with type 2 diabetes (men, premenopausal and postmenopausal women with diabetes), as well as in 105 controls. We stratified the patients into two groups of low Lp(a) levels (Lp(a) <35 mg/dl) and elevated Lp(a) levels (Lp(a) >35 mg/dl). Patients with diabetes had higher serum Lp(a) levels than the controls. Serum Lp(a) levels was significantly higher in women with diabetes than men with diabetes. Lp(a) levels did not differ between male and females in the control group. Premenopausal and postmenopausal women with diabetes did not differ significantly in serum Lp(a) levels. The odds ratio of having a serum Lp(a) level higher than 35 was 5.85 in premenopausal women with diabetes, 5.08 in postmenopausal women with diabetes, 2.41 in men with diabetes and 1.9 in the women in the control group compared to the men in the control group, after adjustment for age and BMI. This observational study clearly indicated that serum Lp(a) levels were significantly higher in women and men with diabetes. The increase in women was independent of menopause. The level of serum Lp(a) had no correlation with lipid parameters in men or women.

show abstract

Impact of markedly elevated serum lipoprotein(a) levels (≥100 mg/dL) on the risk of coronary heart disease

Cited by 16 publications

References 14 publications

Impact of elevated serum lipoprotein (a) concentrations on the risk of coronary heart disease in patients with type 2 diabetes mellitus

Impact of elevated serum lipoprotein (a) concentrations on the risk of coronary heart disease in patients with type 2 diabetes mellitus

Relationship between Lipoprotein(a) and Thyroid Hormones in Hypothyroid Patients

Serum Lipoprotein(a) Levels are Greater in Female than Male Patients with Type‐2 Diabetes

Contact Info

Product

Resources

About